0
Turning Point Therapeutics, Inc. Banner Image

Turning Point Therapeutics, Inc. has reached its limit for free report views

Work for Turning Point Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Turning Point Therapeutics, Inc.

  • Ticker TPTX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Turning Point Therapeutics, Inc. Logo Image
  • 51-200 Employees
  • Based in San Diego, California
Turning Point is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. RepotrectinibMore, which is being studied in a registrational Phase 2 study called TRIDENT-1 in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company’s pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is in a Phase 1 study called SHIELD-1 in patients with advanced or metastatic solid tumors harboring genetic alterations in MET; RET inhibitor TPX-0046, which is in a Phase 1/2 study of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and ALK inhibitor TPX-0131, which is in IND-enabling studies.
Turning Point Therapeutics, Inc.

Most Recent Annual Report

Turning Point Therapeutics, Inc. MOST RECENT 2020 Annual Report

Report Locked. Turning Point Therapeutics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports